Artivion Q1 Revenue Rises 18% as It Secures FDA Approval, Buys Endospan for $135M
Artivion delivered Q1 revenue of $116.3M, up 18% GAAP and 12% constant currency, with net income of $1.4M versus a $0.5M loss a year ago and non-GAAP net income of $4.2M. The company secured FDA approval for the NEXUS Aortic Arch System and agreed to acquire Endospan for $135M.
1. First Quarter Financial Results
Artivion reported total Q1 2026 revenue of $116.3 million, an 18% GAAP increase and 12% growth on a non-GAAP constant currency basis compared to Q1 2025. Net income was $1.4 million, or $0.03 per share, reversing a $0.5 million loss a year earlier, while non-GAAP net income rose to $4.2 million. Adjusted EBITDA climbed 26% to $22.1 million, driven by stent graft growth of 21%, On-X valve sales up 20%, preservation services up 23% and BioGlue up 4% year-over-year.
2. FDA Approval and Acquisition of Endospan
The U.S. FDA granted PMA approval for Artivion’s NEXUS Aortic Arch System for treating aortic arch disease, including chronic dissections. Following this milestone, Artivion exercised its option to acquire Endospan for an upfront purchase price of $135 million, with the transaction expected to close in Q2 2026, expanding its aortic arch portfolio and pipeline.
3. Updated Full-Year 2026 Guidance
Artivion lowered full-year 2026 revenue guidance to $480–$496 million (7%–11% constant currency growth) from a prior range of $486–$504 million, and adjusted EBITDA guidance to $100–$107 million (12%–20% growth) from $105–$110 million. The guidance excludes approximately $8 million of Endospan-related expenses, and U.S. NEXUS sales are expected to be negligible in 2026 ahead of a January 2027 commercial launch.